Table 2.

RRs of grade 3 or higher AEs comparing PARP inhibitors group vs. the control group.

Adverse event type	No. of included trials	PARP inhibitors therapy	Placebo or chemotherapy	RR (95% CI)	P	I2(%)	P
Anemia	11	697/3,202	109/1,732	10.96 (3.14–38.23)	0.0002	91	<0.00001
Thrombocytopenia	9	432/3,002	36/1,572	7.38 (2.10–25.88)	0.002	79	<0.00001
Neutropenia	10	481/3,138	210/1,700	2.91 (1.55–5.44)	0.0008	80	<0.00001
Fatigue	11	162/3,202	34/1,732	2.57 (1.64–4.03)	<0.0001	26	0.21
Nausea	11	89/3,202	19/1,732	2.33 (1.46–3.72)	0.0004	0	0.68
Vomiting	11	63/3,202	23/1,732	1.55 (0.96–2.50)	0.07	0	0.76
Abdominal pain	11	64/3,202	34/1,732	1.08 (0.71–1.63)	0.73	0	0.63
Diarrhea	10	40/2,718	23/1,488	0.99 (0.58–1.67)	0.97	0	0.51
Long-term hematologic eventsa	9	27/3,167	8/1,639	1.40 (0.68–2.87)	0.36	0	0.91

RRs, risk ratios; AEs, adverse events; No., number.

^aLong-term hematologic events referred to myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia, and aplastic anemia.